X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (338994) 338994
Newspaper Article (11004) 11004
Newsletter (3555) 3555
Magazine Article (2391) 2391
Book Chapter (1757) 1757
Transcript (342) 342
Trade Publication Article (308) 308
Book / eBook (296) 296
Government Document (223) 223
Dissertation (106) 106
Reference (98) 98
Book Review (62) 62
Report (62) 62
Publication (31) 31
Web Resource (31) 31
Conference Proceeding (23) 23
Streaming Video (6) 6
Pamphlet (2) 2
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (281115) 281115
female (154284) 154284
male (145461) 145461
middle aged (108379) 108379
adult (97442) 97442
aged (82558) 82558
treatment outcome (68193) 68193
drug therapy, combination (59743) 59743
drug therapy (54969) 54969
pharmacology & pharmacy (51323) 51323
animals (49834) 49834
oncology (49733) 49733
care and treatment (43258) 43258
cancer (37297) 37297
research (36083) 36083
health aspects (32744) 32744
chemotherapy (32432) 32432
therapy (32308) 32308
medicine & public health (32043) 32043
risk factors (31940) 31940
adolescent (30744) 30744
analysis (29126) 29126
clinical trials (27101) 27101
aged, 80 and over (24549) 24549
double-blind (24016) 24016
patients (23965) 23965
drugs (22722) 22722
antineoplastic combined chemotherapy protocols - therapeutic use (22302) 22302
retrospective studies (21197) 21197
dose-response relationship, drug (20976) 20976
child (20537) 20537
efficacy (20001) 20001
time factors (19861) 19861
drug dosages (19551) 19551
young adult (19351) 19351
dosage and administration (19340) 19340
medicine, general & internal (19140) 19140
double-blind method (18833) 18833
drug administration schedule (18758) 18758
prospective studies (18687) 18687
studies (18629) 18629
internal medicine (18012) 18012
antineoplastic combined chemotherapy protocols - adverse effects (16987) 16987
surgery (16733) 16733
mortality (16320) 16320
medicine (16313) 16313
follow-up studies (16271) 16271
medical research (15967) 15967
safety (15860) 15860
management (15146) 15146
hematology (14793) 14793
usage (14481) 14481
clinical neurology (14461) 14461
antineoplastic agents - therapeutic use (14239) 14239
drug combinations (14165) 14165
clinical trials as topic (14132) 14132
risk (14045) 14045
mice (13914) 13914
immunology (13799) 13799
psychiatry (13734) 13734
complications and side effects (13671) 13671
abridged index medicus (13452) 13452
prevention (13319) 13319
infectious diseases (12981) 12981
trial (12867) 12867
pharmacology/toxicology (12710) 12710
pharmacokinetics (12672) 12672
randomized controlled trials as topic (12541) 12541
prognosis (12522) 12522
pharmacology (12300) 12300
research article (12286) 12286
antineoplastic agents - adverse effects (12258) 12258
children (12146) 12146
review (12113) 12113
diagnosis (11961) 11961
disease (11930) 11930
child, preschool (11398) 11398
pediatrics (11393) 11393
drug interactions (11266) 11266
combination (11263) 11263
cardiac & cardiovascular systems (11256) 11256
diabetes (11218) 11218
neurosciences (11128) 11128
gastroenterology & hepatology (10949) 10949
cancer therapies (10887) 10887
toxicity (10759) 10759
administration, oral (10640) 10640
rats (10530) 10530
tumors (10514) 10514
medicine, research & experimental (10466) 10466
hypertension (10360) 10360
survival (10130) 10130
quality of life (10120) 10120
endocrinology & metabolism (10042) 10042
medicine, experimental (9985) 9985
patient outcomes (9653) 9653
metastasis (9470) 9470
drug resistance (9452) 9452
apoptosis (9401) 9401
pain (9353) 9353
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (64) 64
Online Resources - Online (19) 19
Collection Dvlpm't (Acquisitions) - Vendor file (18) 18
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (7) 7
UofT at Mississauga - Stacks (7) 7
UofT at Scarborough - Stacks (7) 7
Dentistry (Harry R Abbott) - Stacks (4) 4
Markham Stouffville Hospital - Stacks (4) 4
Baycrest Hospital - Stacks (3) 3
Gerstein Science - Periodical Stacks (2) 2
Gerstein Science - Reference (2) 2
Providence Healthcare - Reference (2) 2
Scarborough Hospital - Online (2) 2
West Park Healthcare Centre - Stacks (2) 2
Dentistry (Harry R Abbott) - Circulation Desk (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Dentistry (Harry R Abbott) - Processing (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Missing (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Online (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Law (Bora Laskin) - Theses (1) 1
Media Commons - Microtexts (1) 1
New College (Ivey) - Stacks (1) 1
Online (1) 1
Online Resources - Pharmacy (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - Circulation Desk (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Lost (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Bindery (1) 1
UofT at Scarborough - Circulation Desk (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (348132) 348132
German (3865) 3865
Japanese (2205) 2205
French (1990) 1990
Russian (1277) 1277
Spanish (1005) 1005
Chinese (609) 609
Italian (369) 369
Dutch (200) 200
Polish (196) 196
Danish (146) 146
Portuguese (146) 146
Hungarian (124) 124
Czech (115) 115
Norwegian (101) 101
Romanian (73) 73
Bulgarian (65) 65
Swedish (63) 63
Hebrew (47) 47
Turkish (47) 47
Korean (37) 37
Croatian (33) 33
Ukrainian (29) 29
Finnish (28) 28
Arabic (22) 22
Serbian (22) 22
Slovak (13) 13
Lithuanian (8) 8
Bosnian (6) 6
Slovenian (4) 4
Icelandic (3) 3
Persian (3) 3
Afrikaans (1) 1
Indonesian (1) 1
Malay (1) 1
Thai (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 1 - 13
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
The New England journal of medicine, ISSN 0028-4793, 2012, Volume 367, Issue 5, pp. 435 - 444
The combination of anastrozole and fulvestrant — which interfere with estrogen signaling by distinct mechanisms... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | TAMOXIFEN | DOUBLE-BLIND | RANDOMIZED-TRIAL | ENDOCRINE THERAPY | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | HORMONAL-THERAPY | FIRST-LINE THERAPY | Triazoles - administration & dosage | Triazoles - adverse effects | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Aromatase Inhibitors - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Estradiol - adverse effects | Postmenopause | Adult | Female | Aromatase Inhibitors - administration & dosage | Estradiol - administration & dosage | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Cross-Over Studies | Disease-Free Survival | Estrogen Antagonists - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Estrogen Antagonists - adverse effects | Breast Neoplasms - mortality | Aged | Nitriles - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Breast cancer | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Fulvestrant | Statistical analysis | Anastrozole | Estrogen receptors | Tamoxifen | Cancer therapies | Survival | Patients | Post-menopause | Metastases | Chemotherapy | Womens health | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 1935-5548, 2018, Volume 41, Issue 8, pp. 1543 - 1556
The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic... 
Humans | Insulin/administration & dosage | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors/administration & dosage | Sodium-Glucose Transporter 2/antagonists & inhibitors | Hypoglycemic Agents/administration & dosage | Signal Transduction/drug effects | Metformin/administration & dosage | Animals | Diabetes Mellitus, Type 2/drug therapy | Blood Glucose/drug effects | Thiazolidinediones/administration & dosage | Sulfonylurea Compounds/administration & dosage | Drug Therapy, Combination | KIDNEY-DISEASE | GLUCOSE COTRANSPORTER 2 | ADD-ON THERAPY | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | GLYCEMIC CONTROL | GLP-1 RECEPTOR AGONISTS | GLUCAGON-LIKE PEPTIDE-1 | CARDIOVASCULAR OUTCOMES | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN PLUS SULFONYLUREA | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Insulin - administration & dosage | Sodium-Glucose Transporter 2 Inhibitors | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - administration & dosage | Thiazolidinediones - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Metformin - adverse effects | Blood Glucose - drug effects | Hypoglycemic Agents - administration & dosage | Signal Transduction - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Type 2 diabetes | Usage | Analysis | Practice guidelines (Medicine) | Hypoglycemic agents | Dosage and administration | Drug therapy, Combination | Drug therapy | Risk factors
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9971, pp. 857 - 866
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Major and Brief Reports
Journal Article